AU500542B2 - Imidazlidine derivatives and pharmaceutical compositions containing same which have antiandrogenic activity - Google Patents

Imidazlidine derivatives and pharmaceutical compositions containing same which have antiandrogenic activity

Info

Publication number
AU500542B2
AU500542B2 AU19095/76A AU1909576A AU500542B2 AU 500542 B2 AU500542 B2 AU 500542B2 AU 19095/76 A AU19095/76 A AU 19095/76A AU 1909576 A AU1909576 A AU 1909576A AU 500542 B2 AU500542 B2 AU 500542B2
Authority
AU
Australia
Prior art keywords
imidazlidine
derivatives
pharmaceutical compositions
compositions containing
containing same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU19095/76A
Other languages
English (en)
Other versions
AU1909576A (en
Inventor
J. Gibault P. & Bonne C Perronnet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Roussel Uclaf SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf SA filed Critical Roussel Uclaf SA
Publication of AU1909576A publication Critical patent/AU1909576A/en
Application granted granted Critical
Publication of AU500542B2 publication Critical patent/AU500542B2/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72Two oxygen atoms, e.g. hydantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88Nitrogen atoms, e.g. allantoin

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Electromechanical Clocks (AREA)
AU19095/76A 1975-01-29 1976-10-28 Imidazlidine derivatives and pharmaceutical compositions containing same which have antiandrogenic activity Expired AU500542B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FRFRU)75-33 1975-01-29
FR7533084A FR2329276A1 (fr) 1975-10-29 1975-10-29 Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant

Publications (2)

Publication Number Publication Date
AU1909576A AU1909576A (en) 1978-05-04
AU500542B2 true AU500542B2 (en) 1979-05-24

Family

ID=9161795

Family Applications (1)

Application Number Title Priority Date Filing Date
AU19095/76A Expired AU500542B2 (en) 1975-01-29 1976-10-28 Imidazlidine derivatives and pharmaceutical compositions containing same which have antiandrogenic activity

Country Status (18)

Country Link
US (1) US4097578A (US07655688-20100202-C00299.png)
JP (1) JPS6011701B2 (US07655688-20100202-C00299.png)
AU (1) AU500542B2 (US07655688-20100202-C00299.png)
BE (1) BE847742A (US07655688-20100202-C00299.png)
BG (1) BG60533B2 (US07655688-20100202-C00299.png)
CA (1) CA1086751A (US07655688-20100202-C00299.png)
CH (1) CH599164A5 (US07655688-20100202-C00299.png)
DE (1) DE2649925C2 (US07655688-20100202-C00299.png)
DK (1) DK152125C (US07655688-20100202-C00299.png)
ES (1) ES452746A1 (US07655688-20100202-C00299.png)
FR (1) FR2329276A1 (US07655688-20100202-C00299.png)
GB (1) GB1518444A (US07655688-20100202-C00299.png)
GE (1) GEP19970948B (US07655688-20100202-C00299.png)
IE (1) IE43875B1 (US07655688-20100202-C00299.png)
LU (2) LU76085A1 (US07655688-20100202-C00299.png)
NL (2) NL187102C (US07655688-20100202-C00299.png)
SE (1) SE430502B (US07655688-20100202-C00299.png)
SU (1) SU596165A3 (US07655688-20100202-C00299.png)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MC1220A1 (fr) * 1977-10-28 1979-07-20 Hoffmann La Roche Nouveaux derives d'imidazolidine
CA1138334A (en) * 1977-10-28 1982-12-28 Karl Bernauer Pharmaceutical preparations containing certain urea derivatives
FI801184A (fi) * 1979-04-24 1980-10-25 Hoffmann La Roche Foerfarande foer framstaellning av imidazolidinderivat
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
US4775660A (en) * 1984-08-02 1988-10-04 Fernand Labrie Treatment of breast cancer by combination therapy
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
ATE75947T1 (de) * 1984-08-02 1992-05-15 Labrie Fernand Pharmazeutische zusammensetzung fuer die kombinationstherapie von hormonabhaengigem krebs.
IT1214735B (it) * 1986-11-04 1990-01-18 Roussel Maestretti Spa Impiego di 1-(3'-trifluorometil 4'nitrofenil) 4,4-dimetilimidazolin2,5-dione per il trattamento di cancri ormonodipendenti diverso da quello della prostata
US5084472A (en) * 1986-11-04 1992-01-28 Roussel Application of 1-(3'-trifluoromethyl-4'-nitrophenyl)-4,4'-dimethylimidazoline 2,5-dione in the treatment of hormone-dependent cancers other than that of the prostate
FR2619381B1 (fr) * 1987-08-13 1989-12-08 Roussel Uclaf Nouvelles imidazolidines substituees par un radical hydroxymethyle et un radical phenyl substitue, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant et un intermediaire pour leur preparation
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
FR2656302B1 (fr) * 1989-12-22 1992-05-07 Roussel Uclaf Nouveau procede de preparation de l'anandron et derives de l'anandron.
FR2693461B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
USRE35956E (en) * 1991-01-09 1998-11-10 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2671348B1 (fr) * 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) * 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2706456B1 (fr) 1993-06-18 1996-06-28 Rhone Poulenc Agrochimie Dérivés optiquement actifs de 2-imidazoline-5-ones et 2-imidazoline-5-thiones fongicides.
US6002016A (en) * 1991-12-20 1999-12-14 Rhone-Poulenc Agrochimie Fungicidal 2-imidazolin-5-ones and 2-imidazoline-5-thiones
FR2685328B1 (fr) * 1991-12-20 1995-12-01 Rhone Poulenc Agrochimie Derives de 2-imidazoline-5-ones et 2-imidazoline-5-thiones fongicides.
FR2694290B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US6008370A (en) * 1992-11-25 1999-12-28 Rhone-Poulenc Agrochimie Fungicidal-2-alkoxy/haloalkoxy-1-(mono- or disubstituted)amino-4,4-disubstituted-2-imidazolin-5-ones
FR2715402B1 (fr) * 1994-01-05 1996-10-04 Roussel Uclaf Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
TW521073B (en) * 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2724169B1 (fr) * 1994-09-06 1997-01-03 Roussel Uclaf Nouvelles phenylimidazolidines eventuellement substituees, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
FR2725206B1 (fr) * 1994-09-29 1996-12-06 Roussel Uclaf Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US5656651A (en) * 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US7001911B2 (en) 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
US20040077605A1 (en) 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
MXPA02012605A (es) * 2000-06-28 2003-05-14 Squibb Bristol Myers Co Moduladores selectivos del receptor androgeno y metodo para su identificacion, dise°o y uso.
US6953679B2 (en) 2000-09-19 2005-10-11 Bristol-Myers Squibb Company Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
EP1854798A3 (en) 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
WO2003005889A2 (en) * 2001-07-10 2003-01-23 Ams Research Corporation Surgical kit for treating prostate tissue
ES2310622T3 (es) * 2001-12-19 2009-01-16 Bristol-Myers Squibb Company Compuestos heterociclicos condensados y analogos de los mismos, moduladores de la funcion de los receptores nucleares de hormonas.
US7354933B2 (en) * 2003-01-31 2008-04-08 Aventis Pharma Sa Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
FR2850652B1 (fr) * 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
MXPA06001751A (es) * 2003-08-22 2006-05-12 Ligand Pharm Inc Derivados de 6-cicloamino-2-quinolinona como compuestos moduladores de receptor de androgeno.
US7829552B2 (en) 2003-11-19 2010-11-09 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
DE602004031881D1 (de) * 2003-12-19 2011-04-28 Univ California Verfahren und materialien zur beurteilung von prostatakrebstherapien
WO2005099693A2 (en) * 2004-02-24 2005-10-27 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
US8519158B2 (en) * 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
WO2006031715A2 (en) * 2004-09-10 2006-03-23 Janssen Pharmaceutica N.V. Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (sarms)
RS52274B2 (sr) 2005-05-13 2018-05-31 Univ California Jedinjenje diarilhidantoina
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
KR101293935B1 (ko) * 2005-06-17 2013-08-08 리간드 파마슈티칼스 인코포레이티드 안드로겐 수용체 조절 화합물 및 방법
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
FR2896503B1 (fr) * 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
DK2656842T3 (en) 2006-03-27 2016-11-07 Univ California Androgen receptor MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND androgen receptor-ASSOCIATED DISEASES
SG10201408699TA (en) 2006-03-29 2015-02-27 Univ California Diarylthiohydantoin compounds
JP5498168B2 (ja) 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのcetp阻害剤としてのn−((3−ベンジル)−2,2−(ビス−フェニル)−プロパン−1−アミン誘導体
US9232959B2 (en) 2007-01-02 2016-01-12 Aquabeam, Llc Multi fluid tissue resection methods and devices
EP2099375B1 (en) 2007-01-02 2014-09-24 AquaBeam LLC Minimally invasive devices for the treatment of prostate diseases
US20080245375A1 (en) * 2007-04-05 2008-10-09 Medtronic Vascular, Inc. Benign Prostatic Hyperplasia Treatments
UY31432A1 (es) 2007-10-26 2009-05-29 Compuestos de diarilhidantoina
JP5506702B2 (ja) 2008-03-06 2014-05-28 アクアビーム エルエルシー 流体流れ内を伝達される光学エネルギーによる組織切除および焼灼
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
US9848904B2 (en) 2009-03-06 2017-12-26 Procept Biorobotics Corporation Tissue resection and treatment with shedding pulses
FR2944524B1 (fr) * 2009-04-17 2012-11-30 Ipsen Pharma Sas Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
MX355915B (es) 2010-02-16 2018-05-04 Aragon Pharmaceuticals Inc Moduladores del receptor de androgenos y usos de los mismos.
EP2907504B1 (en) 2011-02-08 2017-06-28 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
JP6080872B2 (ja) 2012-02-29 2017-02-15 プロセプト バイオロボティクス コーポレイション 自動化された画像誘導組織切除および治療
EA202190820A1 (ru) 2012-09-26 2021-10-29 Арагон Фармасьютикалз, Инк. Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
CN105431096B (zh) 2013-02-14 2018-07-31 普罗赛普特生物机器人公司 液体消融液体束眼外科手术的方法和装置
EP2959013A2 (en) 2013-02-25 2015-12-30 Novartis AG Novel androgen receptor mutation
CN109965976B (zh) 2013-09-06 2022-05-31 普罗赛普特生物机器人公司 利用致脱脉冲的用于消融组织的装置
BR112016031037B1 (pt) 2014-06-30 2023-02-07 Procept Biorobotics Corporation Aparelho para ablação de tecido vascular
BR112017004431B1 (pt) 2014-09-05 2022-11-01 Procept Biorobotics Corporation Aparelho para tratar um paciente
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
WO2018037310A1 (en) 2016-08-20 2018-03-01 Ftf Pharma Private Limited Pharmaceutical composition comprising an androgen receptor inhibitor
CN107216290B (zh) * 2017-06-12 2021-03-16 陕西科技大学 一种3-丁基-5,5-二甲基海因咪唑季铵盐及其制备方法
WO2019078920A1 (en) 2017-10-16 2019-04-25 Aragon Pharmaceuticals, Inc. ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC RESISTANT PROSTATE CANCER

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB997037A (en) * 1962-03-19 1965-06-30 Ici Ltd New hydrantoin derivatives
JPS4920973B1 (US07655688-20100202-C00299.png) * 1970-05-28 1974-05-29
JPS5136332B1 (US07655688-20100202-C00299.png) * 1970-12-09 1976-10-07
IL45459A (en) * 1973-09-03 1978-01-31 Ciba Geigy Ag 1-(dichlorofluoromethylthio)-3-phenyl-imidazolidine-2,4-dione derivatives their preparation and their use as bactericides and fungicides

Also Published As

Publication number Publication date
ES452746A1 (es) 1977-10-01
DE2649925A1 (de) 1977-05-12
GB1518444A (en) 1978-07-19
FR2329276B1 (US07655688-20100202-C00299.png) 1979-09-14
LU76085A1 (US07655688-20100202-C00299.png) 1977-05-31
DE2649925C2 (de) 1986-08-28
NL930079I2 (nl) 1993-10-01
AU1909576A (en) 1978-05-04
IE43875L (en) 1977-04-29
IE43875B1 (en) 1981-06-17
GEP19970948B (en) 1997-04-18
BE847742A (fr) 1977-04-28
JPS5257176A (en) 1977-05-11
SE430502B (sv) 1983-11-21
NL187102C (nl) 1991-06-03
FR2329276A1 (fr) 1977-05-27
CH599164A5 (US07655688-20100202-C00299.png) 1978-05-12
DK152125C (da) 1988-06-20
JPS6011701B2 (ja) 1985-03-27
NL930079I1 (nl) 1993-09-16
SE7610859L (sv) 1977-04-30
US4097578A (en) 1978-06-27
NL187102B (nl) 1991-01-02
BG60533B2 (bg) 1995-07-28
LU88282I2 (fr) 1994-05-04
DK152125B (da) 1988-02-01
SU596165A3 (ru) 1978-02-28
NL7611576A (nl) 1977-05-03
DK487476A (da) 1977-04-30
CA1086751A (fr) 1980-09-30

Similar Documents

Publication Publication Date Title
AU500542B2 (en) Imidazlidine derivatives and pharmaceutical compositions containing same which have antiandrogenic activity
IL54842A (en) 1-piperidino-phthalazine derivatives,their preparation and pharmaceutical compositions containing them
NZ180529A (en) Erythromyc-9-yl-amine derivatives and pharmaceutical compositions
IL49911A0 (en) New 5-aroylpyrrole derivatives,their preparation and pharmaceutical compositions containing them
DE2861317D1 (en) Cephalosporin derivatives, processes for their preparation and pharmaceutical compositions containing them
IL50869A (en) Heterocyclylthio-ethylimidazole derivatives,their preparation and pharmaceutical compositions containing them
IL56017A (en) 5-cyano-prostacyclin derivatives,their manufacture and pharmaceutical compositions containing them
AU502957B2 (en) Oxadiazolinone derivatives and insecticidal compositions containing them
IL55765A (en) Dehydropyridine derivatives,their preparation and pharmaceutical compositions containing them
GB1537880A (en) 1-triarylalkyl-4-phenyl-4-piperidine-methanols and derivatives and pharmaceutical compositions containing them
IL54535A0 (en) Novel -lactam derivatives, their preparation and pharmaceutical compositions containing them
AU502644B2 (en) Xanthine-containing pharmaceutical compositions
AU507272B2 (en) Pharmaceutical compositions and compounds
NZ188038A (en) Di-orthosubstituted benzene derivatives and pharmaceutical compositions
PH13709A (en) Daunorubicin derivatives and pharmaceutical compositions containing same
NZ182161A (en) Alkoxy-pyridine-carobxamide derivatives and pharmaceutical compositions
IL50335A (en) Diphenylalkylpolyamine derivatives,their preparation and pharmaceutical compositions containing them
IL50156A0 (en) New homophthalimide derivatives,their preparation and pharmaceutical compositions containing them
IL53766A0 (en) 4-diphenylmethylene-1-hydroxybenzyl-piperidine derivatives, their preparation and pharmaceutical compositions containing them
NZ181727A (en) Pyrroline-2-one derivatives and pharmaceutical compositions
DE2860248D1 (en) New cephalosporin derivatives, their preparations and their pharmaceutical compositions
NZ181401A (en) 2-benzopyranone derivatives and pharmaceutical compositions
NZ185267A (en) Derivatives of 1-amino-2hydroxy-3-heterocycloxy-propanes, and pharmaceutical compositions containing them
NZ181146A (en) Benzocycloheptathiophene derivatives and pharmaceutical compositions
IL53030A (en) Derivatives of 9-chloroprednisolone,processes for their preparation and pharmaceutical compositions containing the same